| At the 30-31 October meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS), WTO members continued their discussion on whether to extend the TRIPS Decision adopted at the 12th Ministerial Conference (MC12) to COVID-19 therapeutics and diagnostics. They also reacted to the results of the United States International Trade Commission (USITC) report and a thematic session with external stakeholders dedicated to the issue. Read More |
Categories:
